Jiangsu Theravac Bio pharmaceutical CO.

Nanjing, China

Jiangsu Theravac Bio pharmaceutical CO.

Nanjing, China

Time filter

Source Type

Li J.,Jiangsu Theravac Bio pharmaceutical CO. | Ge J.,Jiangsu Theravac Bio pharmaceutical CO. | Ren S.,Jiangsu Theravac Bio pharmaceutical CO. | Zhou T.,Jiangsu Theravac Bio pharmaceutical CO. | And 15 more authors.
Vaccine | Year: 2015

Hepatitis B virus infection is a non-cytopathic hepatotropic virus which can lead to chronic liver disease and hepatocellular carcinoma. Traditional therapies fail to provide sustained control of viral replication and liver damage in most patients. As an alternative strategy, immunotherapeutic approaches have shown promising efficacy in the treatment of chronic hepatitis B patients. Here, we investigated the efficacy of a novel therapeutic vaccine formulation consisting of two HBV antigens, HBsAg and HBcAg, and CpG adjuvant. This vaccine formulation elicits forceful humoral responses directed against HBsAg/HBcAg, and promotes a Th1/Th2 balance response against HBsAg and a Th1-biased response against HBcAg in both C57BL/6 and HBV transgenic mice. Vigorous cellular immune response was also detected in HBV transgenic mice, for a significantly higher number of HBs/HBc-specific IFN-γ secreting CD4+ and CD8+ T cells was generated. Moreover, vaccinated mice elicited significantly intense in vivo CTL attack, reduced serum HBsAg level without causing liver damage in HBV transgenic mice. In summary, this study demonstrates a novel therapeutic vaccine with the potential to elicit vigorous humoral and cellular response, overcoming tolerance in HBV transgenic mice. © 2015 Elsevier Ltd.


Patent
Jiangsu Theravac Bio Pharmaceutical Co. | Date: 2014-02-26

Disclosed is a composition comprising: i) HBsAg, a fragment thereof, a variant thereof, or the mixture of at least two of them, ii) HBcAg1-X, a fragment thereof, a variant of the antigen or the antigen fragment, or the mixture of at least two of them, wherein X is an integer of from 149 to 183, iii) CpG-ODN, 21 bases long, which is a phosphorothioate oligonucleotide and includes two or more copies of 5-NTCGTT-3 motifs. The use of the composition in the treatment of HBV-infection and HBV-induced diseases, and the therapy methods of HBV-infection and HBV-induced diseases are also disclosed.


Patent
Jiangsu Theravac Bio Pharmaceutical Co. | Date: 2016-01-20

Disclosed is a composition comprising: i) HBsAg, a fragment thereof, a variant thereof, or the mixture of at least two of them, ii) HBcAgl-X, a fragment thereof, a variant of the antigen or the antigen fragment, or the mixture of at least two of them, wherein X is an integer of from 149 to 183, iii) CpG-ODN, 21 bases long, which is a phosphorothioate oligonucleotide and includes two or more copies of 5-NTCGTT-3 motifs. The use of the composition in the treatment of HBV-infection and HBV-induced diseases, and the therapy methods of HBV-infection and HBV-induced diseases are also disclosed.


PubMed | Jiangsu Simcere Pharmaceutical R&D Co., China Pharmaceutical University and Jiangsu Theravac Bio pharmaceutical CO.
Type: Journal Article | Journal: Vaccine | Year: 2015

Hepatitis B virus infection is a non-cytopathic hepatotropic virus which can lead to chronic liver disease and hepatocellular carcinoma. Traditional therapies fail to provide sustained control of viral replication and liver damage in most patients. As an alternative strategy, immunotherapeutic approaches have shown promising efficacy in the treatment of chronic hepatitis B patients. Here, we investigated the efficacy of a novel therapeutic vaccine formulation consisting of two HBV antigens, HBsAg and HBcAg, and CpG adjuvant. This vaccine formulation elicits forceful humoral responses directed against HBsAg/HBcAg, and promotes a Th1/Th2 balance response against HBsAg and a Th1-biased response against HBcAg in both C57BL/6 and HBV transgenic mice. Vigorous cellular immune response was also detected in HBV transgenic mice, for a significantly higher number of HBs/HBc-specific IFN- secreting CD4+ and CD8+ T cells was generated. Moreover, vaccinated mice elicited significantly intense in vivo CTL attack, reduced serum HBsAg level without causing liver damage in HBV transgenic mice. In summary, this study demonstrates a novel therapeutic vaccine with the potential to elicit vigorous humoral and cellular response, overcoming tolerance in HBV transgenic mice.

Loading Jiangsu Theravac Bio pharmaceutical CO. collaborators
Loading Jiangsu Theravac Bio pharmaceutical CO. collaborators